CN1262271C - 用于预防或治疗精神病的氨基甲酸酯化合物 - Google Patents

用于预防或治疗精神病的氨基甲酸酯化合物 Download PDF

Info

Publication number
CN1262271C
CN1262271C CNB028089235A CN02808923A CN1262271C CN 1262271 C CN1262271 C CN 1262271C CN B028089235 A CNB028089235 A CN B028089235A CN 02808923 A CN02808923 A CN 02808923A CN 1262271 C CN1262271 C CN 1262271C
Authority
CN
China
Prior art keywords
formula
purposes
enantiomer
schizophrenia
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028089235A
Other languages
English (en)
Chinese (zh)
Other versions
CN1505507A (zh
Inventor
C·R·普拉塔-萨拉曼
赵柏羽
R·E·特伊曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of CN1505507A publication Critical patent/CN1505507A/zh
Application granted granted Critical
Publication of CN1262271C publication Critical patent/CN1262271C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB028089235A 2001-02-27 2002-02-21 用于预防或治疗精神病的氨基甲酸酯化合物 Expired - Fee Related CN1262271C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27188901P 2001-02-27 2001-02-27
US60/271,889 2001-02-27
US10/081,761 2002-02-21
US10/081,761 US6541513B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating psychotic disorders

Publications (2)

Publication Number Publication Date
CN1505507A CN1505507A (zh) 2004-06-16
CN1262271C true CN1262271C (zh) 2006-07-05

Family

ID=26765939

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028089235A Expired - Fee Related CN1262271C (zh) 2001-02-27 2002-02-21 用于预防或治疗精神病的氨基甲酸酯化合物

Country Status (25)

Country Link
US (1) US6541513B2 (https=)
EP (1) EP1401424B1 (https=)
JP (1) JP4276841B2 (https=)
KR (1) KR100886578B1 (https=)
CN (1) CN1262271C (https=)
AR (1) AR032876A1 (https=)
AT (1) ATE346597T1 (https=)
AU (1) AU2002242296B2 (https=)
BR (1) BR0207829A (https=)
CA (1) CA2439480C (https=)
CZ (1) CZ302412B6 (https=)
DE (1) DE60216457T2 (https=)
DK (1) DK1401424T3 (https=)
ES (1) ES2275844T3 (https=)
HU (1) HUP0303342A3 (https=)
IL (2) IL157588A0 (https=)
MX (1) MXPA03007722A (https=)
NO (1) NO20033801L (https=)
NZ (1) NZ527991A (https=)
PL (1) PL365021A1 (https=)
PT (1) PT1401424E (https=)
RS (1) RS51056B (https=)
RU (1) RU2302240C2 (https=)
TW (1) TWI251486B (https=)
WO (1) WO2002067927A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267629T1 (de) * 2000-07-21 2004-06-15 Ortho Mcneil Pharm Inc Verwendung von carbamat verbindungen zur vorbeugung oder behandlung von neuropathischen- , cluster- und migräneartigen kopfschmerzen
EP1383489B1 (en) * 2001-02-27 2007-05-09 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
IL157594A0 (en) 2001-02-27 2004-03-28 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating anxiety disorders
ATE435014T1 (de) 2001-07-16 2009-07-15 Ortho Mcneil Pharm Inc Carbamate verbindungen zur vorbeugung oder behandlung von neuropathischen schmerzen
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
ES2385087T3 (es) * 2005-07-26 2012-07-18 Sk Biopharmaceuticals Co., Ltd Procedimientos para tratar trastornos relacionados con sustancias
EP2081648A2 (en) * 2006-10-30 2009-07-29 Janssen Pharmaceutica, N.V. Carbamate compounds for use in treating depression
BRPI0718323A2 (pt) * 2006-10-31 2013-11-26 Janssen Pharmaceutica Nv Tratamento de transtornos invasivos do desenvolvimento.
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN105189451A (zh) * 2013-03-12 2015-12-23 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US278380A (en) * 1883-05-29 Thermometer
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
CA2051697C (en) * 1989-06-09 1996-10-08 Malcolm Wilson Moon Heterocyclic amines having central nervous system activity
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
TWI251486B (en) 2006-03-21
NZ527991A (en) 2005-04-29
HUP0303342A2 (hu) 2004-01-28
EP1401424A1 (en) 2004-03-31
ATE346597T1 (de) 2006-12-15
DE60216457D1 (de) 2007-01-11
KR100886578B1 (ko) 2009-03-05
DE60216457T2 (de) 2007-09-20
NO20033801L (no) 2003-10-22
EP1401424B1 (en) 2006-11-29
RS67503A (sr) 2006-12-15
CA2439480A1 (en) 2002-09-06
RU2302240C2 (ru) 2007-07-10
PT1401424E (pt) 2007-02-28
IL157588A0 (en) 2004-03-28
US20020165272A1 (en) 2002-11-07
CZ20032297A3 (cs) 2004-06-16
MXPA03007722A (es) 2004-11-12
CA2439480C (en) 2011-04-26
KR20030076713A (ko) 2003-09-26
DK1401424T3 (da) 2007-02-26
BR0207829A (pt) 2004-06-22
WO2002067927A1 (en) 2002-09-06
PL365021A1 (en) 2004-12-27
JP4276841B2 (ja) 2009-06-10
ES2275844T3 (es) 2007-06-16
IL157588A (en) 2009-12-24
US6541513B2 (en) 2003-04-01
AR032876A1 (es) 2003-11-26
RS51056B (sr) 2010-10-31
NO20033801D0 (no) 2003-08-26
JP2004523556A (ja) 2004-08-05
RU2003128983A (ru) 2005-03-10
CN1505507A (zh) 2004-06-16
AU2002242296B2 (en) 2006-06-29
CZ302412B6 (cs) 2011-05-04
HUP0303342A3 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
JP5901528B2 (ja) 線維筋痛症候群の治療方法
CN1262271C (zh) 用于预防或治疗精神病的氨基甲酸酯化合物
EP2627328B1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
CN1235579C (zh) 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
JP7429942B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
CN1250214C (zh) 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
RS51790B (sr) Upotreba derivata benzo-kondenzovanih heterocikličkih sulfamida za lečenje manije i bipolarnog poremećaja
CN1250215C (zh) 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
AU2002242296A1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
CN101272776B (zh) 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
EP3654960A1 (en) Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
ZA200307469B (en) Carbamate compounds for use in preventing or treating psychotic disorders.
EP1545546B1 (en) Treatment of dyskinesia with 2,3-benzodiazepines
Burat et al. Different molecular targets, one purpose–treatment of depression
CN1802168A (zh) 用于神经元再生和功能恢复的σ配体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060705

Termination date: 20120221